Immunotherapy of allergic rhinitis: New therapeutic opportunities with virus-like particles filled with CpG motifs

American Journal of Rhinology and Allergy

Volumn 27, Issue 3, 2013, Pages 206-212

  Klimek, Ludger ^a   Schendzielorz, Philipp ^a   Mueller, Philipp ^b   Saudan, Philippe ^b   Willers, Joerg ^b  

^a Zentrum für Rhinologie and Allergologie   (Germany)

^b CYTOS BIOTECHNOLOGY AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMB A 1 ANTIGEN; ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; PLACEBO; POLLEN ANTIGEN; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; MAST CELL DEGRANULATION; MEDICAL LITERATURE; MULTICENTER STUDY (TOPIC); MYELOID DENDRITIC CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMACYTOID DENDRITIC CELL; POLLEN ALLERGY; PUBLICATION; RAGWEED POLLEN; RANDOMIZED CONTROLLED TRIAL (TOPIC); TH1 CELL; TH2 CELL; VIRUS LIKE AGENT;

ALLERGENS; CPG ISLANDS; HUMANS; IMMUNOTHERAPY; RHINITIS, ALLERGIC, PERENNIAL; TOLL-LIKE RECEPTORS; TREATMENT OUTCOME; VACCINES, VIRUS-LIKE PARTICLE; VIRUS ASSEMBLY;

EID: 84878303560     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2013.27.3875     Document Type: Article

References (87)

1. Bauchau V, and Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 24: 758-764, 2004.
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63(suppl 86): 8-160, 2008.
3. Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc 31: 375-380, 2010.
4. Bousquet J, Lockey R, and Malling HJ. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102: 558-562, 1998.
5. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 1:CD001936, 2007.
6. Riechelmann H, Schmutzhard J, van der Werf JF, et al. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis. Am J Rhinol Allergy 24:e104-e109, 2010.
7. Wise SK, and Schlosser RJ. Subcutaneous and sublingual immunotherapy for allergic rhinitis: What is the evidence? Am J Rhinol Allergy 26: 18-22, 2012.
8. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341: 468-475, 1999.
9. Eng PA, Reinhold M, and Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 57: 306-312, 2002.
10. Mö ller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 109: 251-256, 2002.
11. Pajno GB, Barberio G, De LF, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 31: 1392-1397, 2001.
12. Winther L, Arnved J, Malling HJ, et al. Side-effects of allergenspecific immunotherapy: A prospective multi-centre study. Clin Exp Allergy 36: 254-260, 2006.
13. Cromwell O, Fiebig H, Suck R, et al. Strategies for recombinant allergen vaccines and fruitful results from first clinical studies. Immunol Allergy Clin North Am 26: 261-281, vii, 2006.
14. Senti G, Martinez Gómez JM, Rettig L, et al. Immunotherapeutic targeting of allergic disease. Inflamm Allergy Drug Targets 5: 243-252, 2006.
15. Rolland JM, Gardner LM, and O'Hehir RE. Allergen-related approaches to immunotherapy. Pharmacol Ther 121: 273-284, 2009.
16. Valenta R, and Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 119: 826-830, 2007.
17. Larché M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 119: 906-909, 2007.
18. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. Proc Natl Acad Sci U S A 105: 17908-17912, 2008.
19. Bachmann MF, and Jennings GT. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10: 787-796, 2010.
20. Jennings GT, and Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem 389: 521-236, 2008.
21. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928-1943, 2007.
22. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369: 2161-2170, 2007.
23. Speiser DE, Schwarz K, Baumgaertner P, et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 33: 848-858, 2010.
24. Cooper CL, Davis HL, Morris ML, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22: 3136-3143, 2004.
25. Akdis M, and Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119: 780-791, 2007.
26. Till SJ, Francis JN, Nouri-Aria K, and Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 113: 1025-1034, 2004.
27. Larché M, Akdis CA, and Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6: 761-771, 2006.
28. Hardy CL, Rolland JM, and O'Hehir RE. Blocking antibodies in allergen immunotherapy: The Yin and Yang. Clin Exp Allergy 34: 510-512, 2004.
29. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 172: 3252-3259, 2004.
30. Wachholz PA, Soni NK, Till SJ, and Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 112: 915-922, 2003.
31. Johnson JE, and Chiu W. Structures of virus and virus-like particles. Curr Opin Struct Biol 10: 229-235, 2000.
32. Zinkernagel RM. On natural and artificial vaccinations. Annu Rev Immunol 21: 515-546, 2003.
33. Ahsan F, Rivas IP, Khan MA, and Torres Suarez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. J Control Release 79: 29-40, 2002.
34. Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev 50: 3-20, 2001.
35. Reddy ST, Rehor A, Schmoekel HG, et al. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 112: 26-34, 2006.
36. Manolova V, Flace A, Bauer M, et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 38: 1404-1413, 2008.
37. Pashine A, Valiante NM, and Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11:S63- S68, 2005.
38. Yewdell JW. Designing CD8+ T cell vaccines: It's not rocket science (yet). Curr Opin Immunol 22: 402-410, 2010.
39. Tewalt EF, Grant JM, Granger EL, et al. Viral sequestration of antigen subverts cross presentation to CD8(-) T cells. PLoS Pathog 5:e1000457, 2009.
40. Steinman RM, Bonifaz L, Fujii S, et al. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv Exp Med Biol 560: 83-97, 2005.
41. Colonna M, Trinchieri G, and Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 5: 1219-1226, 2004.
42. Plotkin SA. Vaccines: Past, present and future. Nat Med 11:S5-S11, 2005.
43. Bachmann MF, Rohrer UH, Kündig TM, et al. The influence of antigen organization on B cell responsiveness. Science 262: 1448-1451, 1993.
44. Jegerlehner A, Storni T, Lipowsky G, et al. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol 32: 3305-3314, 2002.
45. Pasare C, and Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 438: 364-368, 2005.
46. Eckl-Dorna J, and Batista FD. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigenspecific plasma cell formation. Blood 113: 3969-3977, 2009.
47. Kündig TM, Shahinian A, Kawai K, et al. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 5: 41-52, 1996.
48. Tritto E, Mosca F, and De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 27: 3331-3334, 2009.
49. Wilcock LK, Francis JN, and Durham SR. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin Exp Allergy 34: 1373-1378, 2004.
50. Gatto D, Ruedl C, Odermatt B, and Bachmann MF. Rapid response of marginal zone B cells to viral particles. J Immunol 173: 4308-4316, 2004.
51. Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 10: 499-511, 2011.
52. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471-484, 2006.
53. Agrawal S, and Gupta S. TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol 31: 89-98, 2011.
54. Fransson M, Benson M, Erjefalt JS, et al. Expression of Toll-like receptor 9 in nose, peripheral blood and bone marrow during symptomatic allergic rhinitis. Respir Res 8:17, 2007.
55. Lebre MC, van der Aar AM, van BaarsenL, et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 127: 331-341, 2007.
56. Huber JP, Ramos HJ, Gill MA, and Farrar JD. Cutting edge: Type I IFN reverses human Th2 commitment and stability by suppressing GATA3. J Immunol 185: 813-817, 2010.
57. Kanzler H, Barrat FJ, Hessel EM, and Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13: 552-559, 2007.
58. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 117: 1184-1194, 2007.
59. Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 4: 289-294, 2007.
60. Dorn A, and Kippenberger S. Clinical application of CpG-, non- CpG-, and antisense oligodeoxynucleotides as immunomodulators. Curr Opin Mol Ther 10: 10-20, 2008.
61. Jahrsdö rfer B, and Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 3: 27-32, 2008.
62. Vollmer J, and Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 61: 195-204, 2009.
63. Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther 22: 77-89, 2012.
64. Halperin SA, Van Nest G, Smith B, et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21: 2461-2467, 2003.
65. Cooper CL, Davis HL, Morris ML, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: A double-blind phase I/II study. J Clin Immunol 24: 693-701, 2004.
66. Friedberg JW, Kim H, McCauley M, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: Increased interferon-alpha/ beta-inducible gene expression, without significant toxicity. Blood 105: 489-495, 2005.
67. Speiser DE, Liénard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115: 739-746, 2005.
68. Hofmann MA, Kors C, Audring H, et al. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 31: 520-527, 2008.
69. Carpentier A, Laigle-Donadey F, Zohar S, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 8: 60-66, 2006.
70. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355: 1445-1455, 2006.
71. McHutchison JG, Bacon BR, Gordon SC, et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46: 1341-1349, 2007.
72. Kündig TM, Senti G, Schnetzler G, et al. Der p 1 peptide on viruslike particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 117: 1470-1476, 2006.
73. Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 39: 562-570, 2009.
74. Stelmach I, Smejda K, Jerzynska J, et al. Decreased markers of atopy in children with presumed early exposure to allergens, unhygienic conditions, and infections. Ann Allergy Asthma Immunol 99: 170-177, 2007.
75. Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: A phase IIb study. Clin Exp Allergy 41: 1305-1312, 2011.
76. Hessel EM, Chu M, Lizcano JO, et al. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J Exp Med 202: 1563-1573, 2005.
77. Jagannathan M, Hasturk H, Liang Y, et al. TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. J Immunol 183: 7461-7470, 2009.
78. Matsushima H, Yamada N, Matsue H, and Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skinderived mast cells but not from bone marrow-derived mast cells. J Immunol 173: 531-541, 2004.
79. Kline JN. Eat dirt: CpG DNA and immunomodulation of asthma. Proc Am Thorac Soc 4: 283-288, 2007.
80. Mellor AL, Baban B, Chandler PR, et al. Cutting edge: CpG oligonucleotides induce splenic CD19- dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 175: 5601-5605, 2005.
81. Strachan DP. Hay fever, hygiene, and household size. BMJ 299: 1259-1260, 1989.
82. Ball TM, Castro-Rodriguez JA, Griffith KA, et al. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. N Engl J Med 343: 538-543, 2000.
83. Braun-Fahrländer C, Riedler J, Herz U, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 347: 869-877, 2002.
84. Riedler J, Braun-Fahrländer C, Eder W, et al. Exposure to farming in early life and development of asthma and allergy: A cross-sectional survey. Lancet 358: 1129-1133, 2001.
85. Akdis CA, and Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 127: 18-27, 2011.
86. Ito T, Yang M, Wang YH et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 204: 105-115, 2007.
87. Zhang LF, Zhou J, Chen S, et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 18: 1051-1058, 2000.